Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Bemnifosbuvir-Ruzasvir versus Sofosbuvir-Velpatasvir in Chronic Hepatitis C Virus Infection
2025-521096-31-00Phase 3Authorised
- Sponsor
- Atea Pharmaceuticals Inc.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial in chronic hepatitis C (CHC) comparing Bemnifosbuvir/Ruzasvir FDC with Sofosbuvir/Velpatasvir (2 arms). Primary endpoint: Proportion of subjects achieving HCV RNA < LLOQ at study week 24. Planned start Sep 2025; status: authorised.
02
Drugs
bemnifosbuvir + ruzasvirsofosbuvir + velpatasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2025-521096-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521096-31-00.